Ipca Laboratories（IPCALAB）株式概要
製薬会社であるイプカ・ラボラトリーズ・リミテッドは、インド、ヨーロッパ、アフリカ、アメリカ大陸、アジア、CIS、オーストラレーシアにおいて、さまざまな治療分野向けの製剤や原薬（API）を製造・販売している。 詳細
IPCALAB Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ipca Laboratories Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | ₹1,734.20 |
| 52週高値 | ₹1,944.90 |
| 52週安値 | ₹1,251.60 |
| ベータ | 0.035 |
| 1ヶ月の変化 | -8.76% |
| 3ヶ月変化 | 5.34% |
| 1年変化 | 26.96% |
| 3年間の変化 | 97.57% |
| 5年間の変化 | 37.40% |
| IPOからの変化 | 4,463.68% |
最新ニュース
ナラティブ更新 • Aug 15
IPCALAB: Amalgamation Meeting Will Drive Future Upside Potential
Analysts have raised their price target for Ipca Laboratories from ₹1,968 to ₹2,050, citing updated assumptions that reflect a slightly lower discount rate, a modestly adjusted revenue growth outlook, a higher profit margin, and a marginally lower future P/E multiple. What's in the News Ipca Laboratories has scheduled a board meeting on Jun 26, 2026 to consider approval of a Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd.ナラティブ更新 • Jul 17
IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential
The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.Recent updates
ナラティブ更新 • Aug 15
IPCALAB: Amalgamation Meeting Will Drive Future Upside Potential
Analysts have raised their price target for Ipca Laboratories from ₹1,968 to ₹2,050, citing updated assumptions that reflect a slightly lower discount rate, a modestly adjusted revenue growth outlook, a higher profit margin, and a marginally lower future P/E multiple. What's in the News Ipca Laboratories has scheduled a board meeting on Jun 26, 2026 to consider approval of a Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd.ナラティブ更新 • Jul 17
IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential
The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.
ナラティブ更新 • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.
ナラティブ更新 • Jun 19
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Analysts have lifted their price target for Ipca Laboratories stock to ₹1,720 from ₹1,655, reflecting updated assumptions that combine slightly different views on revenue growth, profit margins and future P/E levels. What’s in the News for Ipca Laboratories A board meeting of Ipca Laboratories is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.ナラティブ更新 • Jun 04
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.分析記事 • Jun 03
Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...ナラティブ更新 • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).ナラティブ更新 • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).ナラティブ更新 • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).ナラティブ更新 • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.ナラティブ更新 • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).ナラティブ更新 • Feb 20
IPCALAB: Upcoming Board Results Review Will Support Upbeat Long Term Outlook
Analysts have nudged their fair value estimate for Ipca Laboratories up from about ₹1,565 to roughly ₹1,634, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for February 13, 2026, to review and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025.分析記事 • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...分析記事 • Feb 12
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブ更新 • Feb 06
IPCALAB: Upcoming Results Review Will Support Measured Outlook And Modest Assumption Shifts
Analysts have nudged their price target for Ipca Laboratories slightly higher, citing modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and record standalone unaudited financial results for the third quarter ended December 31, 2025.ナラティブ更新 • Jan 23
IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential
Analysts have inched up their fair value estimate for Ipca Laboratories to ₹1,731 per share from ₹1,730 per share, citing updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple in their models. What's in the News Board meeting scheduled for February 13, 2026, to consider and record standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).分析記事 • Jan 21
Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 45.1x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...ナラティブ更新 • Jan 08
IPCALAB: Board Meeting Schedule And Stable Assumptions Will Shape Balanced Outlook
Analysts have slightly raised their price target on Ipca Laboratories to ₹1,555 from ₹1,552, citing small adjustments to long term assumptions on revenue growth, profit margin and future P/E multiples. What's in the News Board meeting scheduled on Oct 17, 2025, at 17:00 Indian Standard Time (company filing) Board meeting set for Nov 13, 2025, to consider and record Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended Sep 30, 2025 (company filing) Valuation Changes Fair Value: The analyst fair value estimate has moved marginally higher from ₹1,551.82 to ₹1,555.06 per share.ナラティブ更新 • Dec 24
IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential
Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).ナラティブ更新 • Dec 10
IPCALAB: Biosimilar Partnership And Board Meetings Will Shape Balanced Outlook
Analysts have nudged their price target for Ipca Laboratories slightly higher to approximately ₹1,552 from about ₹1,543, reflecting modestly improved valuation multiples, even though there were only minor trims to long term revenue growth and profit margin assumptions. What's in the News Ipca Laboratories and BioSimilar Sciences PR LLC entered a Technology Transfer and Joint Development Agreement to shift late stage development, clinical manufacturing, and commercial supply of a next generation anti cancer or anti inflammatory monoclonal antibody biosimilar to BSS sterile campus in Aguadilla, Puerto Rico (company announcement) A board meeting is scheduled on October 17, 2025, at 17:00 Indian Standard Time to review corporate matters (company filing) A board meeting is set for November 13, 2025, to consider and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value Estimate has risen slightly from around ₹1,543 to about ₹1,552, reflecting a modestly higher intrinsic value.分析記事 • Dec 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...ナラティブ更新 • Nov 26
IPCALAB: Technology Partnership and Upcoming Board Meetings Will Influence Outlook
Narrative Update on Ipca Laboratories Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.ナラティブ更新 • Nov 11
IPCALAB: Technology Agreement With BioSimilar Sciences Will Drive Future Expansion
Analysts have raised their price target for Ipca Laboratories from ₹1,501.41 to ₹1,529.94, citing updated model assumptions and slight adjustments to long-term growth and margin forecasts. What's in the News Ipca Laboratories held a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time.分析記事 • Oct 19
Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Ipca...分析記事 • Sep 05
If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...分析記事 • Jul 08
Ipca Laboratories (NSE:IPCALAB) Will Pay A Dividend Of ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...分析記事 • Jun 24
Ipca Laboratories' (NSE:IPCALAB) Dividend Will Be ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...分析記事 • Jun 01
Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Ipca Laboratories Limited ( NSE:IPCALAB ) released its yearly result to the market...分析記事 • May 22
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 51.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...分析記事 • Feb 16
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders might have noticed that Ipca Laboratories Limited ( NSE:IPCALAB ) filed its third-quarter result this time...分析記事 • Jan 10
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Dec 20
Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
With a price-to-earnings (or "P/E") ratio of 61.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...
新しいナラティブ • Dec 12
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.分析記事 • Nov 17
Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
The board of Ipca Laboratories Limited ( NSE:IPCALAB ) has announced that it will pay a dividend of ₹2.00 per share on...分析記事 • Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Ipca Laboratories Limited's ( NSE:IPCALAB ) price-to-earnings (or "P/E") ratio of 61.7x might make it look like a...分析記事 • Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Ipca Laboratories Limited ( NSE:IPCALAB ) recently...分析記事 • May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 31x, you may consider Ipca...分析記事 • Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
With a price-to-earnings (or "P/E") ratio of 61.8x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...分析記事 • Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...株主還元
| IPCALAB | IN Pharmaceuticals | IN 市場 | |
|---|---|---|---|
| 7D | -0.09% | -0.3% | -0.4% |
| 1Y | 27.0% | 16.1% | 4.6% |
業界別リターン: IPCALAB過去 1 年間で16.1 % の収益を上げたIndian Pharmaceuticals業界を上回りました。
リターン対市場: IPCALAB過去 1 年間で4.6 % の収益を上げたIndian市場を上回りました。
価格変動
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
安定した株価: IPCALAB 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: IPCALABの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1949 | 17,210 | Pranay Godha | www.ipca.com |
製薬会社であるイプカ・ラボラトリーズ・リミテッドは、インド、欧州、アフリカ、米州、アジア、CIS、オーストラレーシアにおいて、様々な治療分野向けの製剤や原薬（API）を製造・販売している。同社は、降圧剤、抗マラリア剤、利尿剤、DMARD、駆虫剤などの治療分野でAPIを提供している。また、アレルギー、抗腫瘍・抗がん剤、関節炎治療剤、抗てんかん剤、降圧剤、心臓病、糖尿病、皮膚病、糖尿病、軟膏・保護剤、発熱、消化器病、血液病、蠕虫などの治療分野において、ジェネリック医薬品やブランド製剤を提供している、血液学、蠕虫学、肝保護薬、免疫抑制薬、感染症、マラリア、神経学、神経障害性疼痛、非ステロイド性抗炎症薬、栄養補助食品、眼科、経口糖尿病薬、整形外科、プロバイオティクス、精神科、呼吸器科、リウマチ科、泌尿器科。また、世界中に製品を輸出している。年に設立され、インドのムンバイを拠点としている。
Ipca Laboratories Limited 基礎のまとめ
| IPCALAB 基礎統計学 | |
|---|---|
| 時価総額 | ₹439.97b |
| 収益（TTM） | ₹13.10b |
| 売上高(TTM) | ₹101.19b |
33.6x
PER（株価収益率4.3x
P/SレシオIPCALAB は割高か？
公正価値と評価分析を参照収益と収入
| IPCALAB 損益計算書（TTM） | |
|---|---|
| 収益 | ₹101.19b |
| 売上原価 | ₹32.67b |
| 売上総利益 | ₹68.52b |
| その他の費用 | ₹55.42b |
| 収益 | ₹13.10b |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 51.63 |
| グロス・マージン | 67.71% |
| 純利益率 | 12.94% |
| 有利子負債／自己資本比率 | 7.4% |
IPCALAB の長期的なパフォーマンスは？
過去の実績と比較を見る| Ipca Laboratories 配当日 | |
|---|---|
| 配当落ち日 | Aug 07 2026 |
| 配当支払日 | Sep 10 2026 |
| 配当落ちまでの日数 | 10 days |
| 配当支払日までの日数 | 24 days |
IPCALAB 配当は確実ですか？
IPCALAB 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/16 01:59 |
| 終値 | 2026/08/14 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Ipca Laboratories Limited 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。39
| アナリスト | 機関 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |